---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009737"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T21:59:52.023552+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.

## Summary
- Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.
- FY2023 adjusted EBITDA $4.5M (net of one-time charges) vs -$1.2M in 2022, a 463% reported improvement.
- Cash collections for FY2023 $40.4M (+29% YoY); cash balance at Dec 31, 2023 was $3.5M.
- Dr. Nicole Massoll appointed Chief Medical Officer effective March 2024.
- 10-K expected week of March 19, 2024; preliminary results subject to final audit.

## SEC filing metadata
- accession: 0001493152-24-009737
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/0001493152-24-009737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009737
- JSON: https://secwatch.observer/filing/0001493152-24-009737.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009737.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Result: preliminary results
  source text: On March 7, 2024, Interpace Biosciences, Inc. issued a press release announcing its preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/0001493152-24-009737-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.